How big is Sonoma Pharmaceuticals, Inc.?

As of Jun 18, Sonoma Pharmaceuticals, Inc. has a market capitalization of 4.77 million, with net sales of 13.97 million and a net profit of -3.75 million over the latest four quarters. The company reported shareholder's funds of 6.14 million and total assets of 14.89 million as of Mar 24.

Market Cap: As of Jun 18, Sonoma Pharmaceuticals, Inc. has a market capitalization of 4.77 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sonoma Pharmaceuticals reported net sales of 13.97 million and a net profit of -3.75 million.<BR><BR>Balance Sheet Snapshot: As of Mar 24, the company reported shareholder's funds of 6.14 million and total assets of 14.89 million.

What does Sonoma Pharmaceuticals, Inc. do?

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and marketing solutions for dermatological conditions and advanced tissue care. As of December 2024, it reported net sales of $4 million and a net loss of $1 million, with a market cap of $4.77 million.

Overview:<BR>Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets solutions for the management of dermatological conditions and advanced tissue care, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Dec 2024) <BR>Market-cap: USD 4.77 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.16 <BR>Return on Equity: -78.37% <BR>Price to Book: 1.08<BR><BR>Contact Details:<BR>Address: 645 Molly Lane, Suite 150, WOODSTOCK GA: 30189 <BR>Tel: 1 617 2430050 <BR>Fax: 1 707 2830551 <BR>Website: https://sonomapharma.com/

Should I buy, sell or hold Sonoma Pharmaceuticals, Inc.?

Who are in the management team of Sonoma Pharmaceuticals, Inc.?

As of March 2022, the management team of Sonoma Pharmaceuticals, Inc. includes Lead Independent Director Jerry McLaughlin, Independent Directors Sharon Barbari, Jay Birnbaum, and Philippe Weigerstorfer, who oversee the company's strategic direction and governance.

As of March 2022, the management team of Sonoma Pharmaceuticals, Inc. includes the following individuals: <BR><BR>- Mr. Jerry McLaughlin, who serves as the Lead Independent Director.<BR>- Ms. Sharon Barbari, who is an Independent Director.<BR>- Dr. Jay Birnbaum, also an Independent Director.<BR>- Mr. Philippe Weigerstorfer, who holds the position of Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Is Sonoma Pharmaceuticals, Inc. technically bullish or bearish?

As of September 9, 2025, Sonoma Pharmaceuticals, Inc. shows a mildly bullish trend with mixed technical indicators, having underperformed the S&P 500 recently but outperformed it year-to-date.

As of 9 September 2025, the technical trend for Sonoma Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a bullish stance, but the weekly RSI is bearish. Bollinger Bands show a mildly bullish trend in both weekly and monthly perspectives. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory indicates a mildly bearish weekly trend with no clear monthly trend. The OBV is mildly bearish weekly with no trend monthly.<BR><BR>In terms of returns, the stock has underperformed the S&P 500 over the past week and month, with returns of -6.37% and -20.37% compared to the S&P 500's 1.05% and 2.33%, respectively. However, year-to-date, the stock has outperformed the S&P 500 with a return of 58.36% versus 12.22%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals from various indicators.